Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 May 16, 2018 Announcements in Conjunction with TH Annual Meeting May 16, 2018 TH Provides Update on Trogarzo™ Prescriptions and Reimbursement Status May 11, 2018 TH Announces that National Institute of Health will Support Study of EGRIFTA® in Non-HIV Patients with Non-Alcoholic Fatty Liver Disease May 01, 2018 FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION) Apr 30, 2018 THERATECHNOLOGIES ANNOUNCES THAT TROGARZO™ (IBALIZUMAB-UIYK) INJECTION IS NOW AVAILABLE IN THE U.S. Apr 30, 2018 THERATECHNOLOGIES’ CEO AND CFO TO ATTEND BLOOM BURTON HEALTHCARE INVESTOR CONFERENCE IN TORONTO Apr 24, 2018 Theratechnologies to Seek Regulatory Approval of Trogarzo™ in Europe Apr 05, 2018 Theratechnologies Announces Financial Results for First Quarter of 2018 Mar 29, 2018 Theratechnologies to Announce Financial Results for First Quarter 2018 Mar 08, 2018 New Positive Data on TROGARZO™ (ibalizumab-uiyk) injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections First page « Previous page ‹ … Page 23 Page 24 Page 25 Page 26 Current page 27 Page 28 Page 29 Page 30 Page 31 … Next page › Last page » Displaying 261 - 270 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
May 11, 2018 TH Announces that National Institute of Health will Support Study of EGRIFTA® in Non-HIV Patients with Non-Alcoholic Fatty Liver Disease
May 01, 2018 FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION)
Apr 30, 2018 THERATECHNOLOGIES ANNOUNCES THAT TROGARZO™ (IBALIZUMAB-UIYK) INJECTION IS NOW AVAILABLE IN THE U.S.
Apr 30, 2018 THERATECHNOLOGIES’ CEO AND CFO TO ATTEND BLOOM BURTON HEALTHCARE INVESTOR CONFERENCE IN TORONTO
Mar 08, 2018 New Positive Data on TROGARZO™ (ibalizumab-uiyk) injection and EGRIFTA® (tesamorelin for injection) Presented at 25th Conference on Retroviruses and Opportunistic Infections
